

James Heyward

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7839497/publications.pdf>

Version: 2024-02-01

17
papers

715
citations

758635

12
h-index

996533

15
g-index

19
all docs

19
docs citations

19
times ranked

1024
citing authors

#	ARTICLE	IF	CITATIONS
1	Telemedicine and Office-Based Care for Behavioral and Psychiatric Conditions During the COVID-19 Pandemic in the United States. <i>Annals of Internal Medicine</i> , 2021, 174, 428-430.	2.0	23
2	Lower Use of Biologics for the Treatment of Asthma in Publicly Insured Individuals. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3969-3976.	2.0	28
3	Assessing and communicating heterogeneity of treatment effects for patient subpopulations: Keynote and panel discussion on communicating heterogeneous treatment effects across populations. <i>Pharmaceutical Statistics</i> , 2021, 20, 965-978.	0.7	0
4	Ambulatory <scp>noninsulin</scp> treatment of type 2 diabetes mellitus in the United States, 2015 to 2019. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1843-1850.	2.2	9
5	Primary care physiciansâ€™ preparedness to treat opioid use disorder in the United States: A cross-sectional survey. <i>Drug and Alcohol Dependence</i> , 2021, 225, 108811.	1.6	20
6	Trends in Insulin Types and Devices Used by Adults With Type 2 Diabetes in the United States, 2016 to 2020. <i>JAMA Network Open</i> , 2021, 4, e2128782.	2.8	16
7	Evaluation of the Extended-Release/Long-Acting Opioid Prescribing Risk Evaluation and Mitigation Strategy Program by the US Food and Drug Administration. <i>JAMA Internal Medicine</i> , 2020, 180, 301.	2.6	25
8	Key Evidence Supporting Prescription Opioids Approved by the U.S. Food and Drug Administration, 1997 to 2018. <i>Annals of Internal Medicine</i> , 2020, 173, 956-963.	2.0	2
9	Use and Content of Primary Care Office-Based vs Telemedicine Care Visits During the COVID-19 Pandemic in the US. <i>JAMA Network Open</i> , 2020, 3, e2021476.	2.8	332
10	Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2020, 15, e0234065.	1.1	59
11	Assessing the Opioid Analgesic Risk Evaluation and Mitigation Strategy Programâ€™Reply. <i>JAMA Internal Medicine</i> , 2020, 180, 916.	2.6	0
12	Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 676.	3.8	30
13	Coverage of Nonpharmacologic Treatments for Low Back Pain Among US Public and Private Insurers. <i>JAMA Network Open</i> , 2018, 1, e183044.	2.8	98
14	Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial Insurers. <i>JAMA Network Open</i> , 2018, 1, e180235.	2.8	37
15	The Value of U.S. Pharmacopeial Standards: A Review of the Literature. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 2611-2617.	1.6	7
16	Setting Priorities for Diabetic Retinopathy Clinical Research and Identifying Evidence Gaps. <i>Ophthalmology Retina</i> , 2017, 1, 94-102.	1.2	14
17	Integrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: a protocol for a systematic review. <i>Systematic Reviews</i> , 2015, 4, 143.	2.5	15